Asia
Walvax Biotechnology's Phase 3 Trial of Pneumococcal Polysaccharide Vaccine in Indonesia Meets Preset Objectives
Walvax Biotechnology's (SHE:300142) phase 3 trial of its 13-valent pneumococcal polysaccharide conjugate vaccine in Indonesia met preset objectives, according to a Wednesday filing with the Shenzhen bourse.The trial targeted Indonesian infants aged 6 to 8 weeks to test the immunogenicity and safety of the vaccine.
SHE:300142
